Xeris Biopharma Holdings, Inc. held its Annual Meeting of stockholders and approved the First Amendment to the Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, which removes the evergreen provision and increases the aggregate number of shares available by 6,636,632 additional shares.